Hepatitis A Vaccine

Contact AIM Action Biopharmaceutical Co., Ltd. today and let us be your supplier of Adult Hepatitis A Vaccine. The Hepatitis A vaccine is crucial for adults who frequently travel, attend social events, have occupational exposure risks, or are responsible for protecting their families.

Currently, this vaccine is included in the procurement and stocking catalogs of many local disease control systems, making it a convenient and preferred choice for protecting adult liver health and building family immunity.

What is the Adult Hepatitis A Vaccine?

AIM Action Biopharmaceutical's Adult Hepatitis A Vaccine is a preventative product specifically optimized for the immune system characteristics of individuals aged 15 and older.  Adults are at a relatively higher risk of exposure to the Hepatitis A virus due to work stress, frequent social interactions, and increased travel.

Unlike the pediatric formulation, this product contains 640 EU of Hepatitis A virus antigen per 1.0 ml. This dosage has been clinically proven to effectively stimulate the adult body to produce sufficient and long-lasting protective antibodies.

With strong protection and convenient administration as its core features, this vaccine provides reliable liver protection for busy adults through a two-dose schedule (0 and 6 months), seamlessly integrating health protection into modern life.

Product Ingredients

The inactivated hepatitis A vaccine is a preparation made from the hepatitis A virus (HAV) strain LV8, cultured in human diploid cell line KMB17. The viral suspension is purified and inactivated after culture and harvesting. An appropriate amount of aluminum hydroxide adjuvant is added to the vaccine. This product is a slightly milky suspension, which may show stratification and sedimentation; it can be dispersed by shaking.

Active ingredient: Inactivated hepatitis A virus.

Excipients: Aluminum hydroxide, 2-phenoxyethanol, glycine, sodium bisulfite, sodium hydroxide, and phosphate-buffered saline (PBS).

Administration and Dosage

(1) Shake well before use. Inject single human dose im.at deltoid insertion area of the lateral upper arm.

(2) Eligibles over 15 years old (excluding 15 years old) should be given the adult dose, with 1 dose of vaccine for initial immunization and 1 dose of vaccine for booster immunization at 6 months interval. Each dose is 1.0 ml.

Product Features

1. Precise Dosage, High Efficacy: The Adult Hepatitis A Vaccine has a high antigen content (640 EU) specifically designed for adults, which can more quickly and strongly stimulate the adult immune system to produce protective antibodies, shortening the immunological window period.

2. Convenient Schedule, Easy to Follow: The standard "0, 6 months" two-dose schedule has a reasonable time span, making it easy to remember and schedule, suitable for busy adults to complete the full course of immunization.

3. Safe and Gentle, Less Burden:  The vaccine is produced using human diploid cells and inactivation technology, resulting in a low incidence of systemic adverse reactions.  It does not affect normal work and life after vaccination, providing a more comfortable experience.

4. Long-lasting Protection, Long-term Guarantee: After completing the full course of vaccination, it can provide long-term or even lifelong immune protection. A one-time investment provides lasting defense against hepatitis A, offering a high return on health investment.

Main Application Scenarios

● High-risk occupational groups: Food service workers, kindergarten teachers, healthcare workers, etc., who require vaccination due to their profession or because they belong to a high-risk group.  Hepatitis A vaccination is both self-protection and a professional requirement.

● Frequent travelers and business professionals: Especially those traveling to areas with moderate to high prevalence of hepatitis A, vaccination is an essential health preparation before travel.

● Health management for young and middle-aged adults: Vaccination is part of proactive health management, providing basic protection against liver disease for socially active individuals who frequently dine out or attend social events.

● Core of family protection: Vaccination of key family members not only protects themselves but also reduces the risk of transmitting the virus to elderly or young children in the family, building a family immunity barrier.

The Actual Effects of Vaccination

China was once a high-endemic area for hepatitis A. With the large-scale introduction of hepatitis A vaccines, the reported incidence has declined markedly.

AIM’s inactivated hepatitis A vaccine has been incorporated into the Expanded Program on Immunization (EPI) in nine provincial-level jurisdictions—Jiangsu, Shanghai, Beijing, Tianjin, Zhejiang, Hubei, Hainan, Inner Mongolia, and Qinghai. Cumulative distribution has exceeded 10 million doses, of which approximately 7 million were provided through the EPI, accounting for roughly 30 % of the total. These efforts have driven the national hepatitis A incidence rate down from 5.98 per 100,000 in 2007 to 0.74 per 100,000 in 2022.

Chinese Center for Disease Control and Prevention. Annual Surveillance Reports of Notifiable Infectious Diseases in China, 1990–2021